Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002165 · ClinicalTrials.gov registry record · NA
Viracept Expanded Access Program
A NA study, sponsored by Agouron Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
NCT00002165: Completed NA study, sponsored by Agouron Pharmaceuticals.
NCT00002165 is a NA study that has completed, run by Agouron Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002165, a NA study, has completed, sponsored by Agouron Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To make nelfinavir mesylate (Viracept) available for treatment of HIV positive patients who are unable to take the three commercially available protease inhibitors (because of failure, intolerance, or contraindication) and who have a CD4 cell count of \<= 50. To obtain additional information on the safety profile of nelfinavir mesylate (Viracept). (PER AMENDMENT 1/8/97: People now qualify for the Viracept Program if they are unable to take indinavir and/or ritonavir due to intolerance, contraindication or prior failure.)
Interventions
- DRUG Nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002165 record still lists
NCT00002165 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Nelfinavir mesylate is the first listed.
NCT00002165 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002165 about?
NCT00002165 is a clinical study titled "Viracept Expanded Access Program". To make nelfinavir mesylate (Viracept) available for treatment of HIV positive patients who are unable to take the three commercially available protease inhibitors (because of failure, intolerance, or contraindication) and who have a CD4 cell count of \<= 50. To obtain additional information on the ...
What is the current status of trial NCT00002165?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002165?
The interventions under investigation include: Nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT00002165?
This trial is sponsored by Agouron Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.